Compare LTC Properties Inc (LTC) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
LTC Properties Inc vs Merck & Co., Inc. — how do they compare? LTC Properties Inc trades at $41.74 (market cap $2.15B), while Merck & Co., Inc. trades at $126.29 (market cap $307.25B). The key difference: Merck & Co., Inc. is far larger — about 142.9× LTC Properties Inc's market cap, and LTC Properties Inc pays the higher dividend (5.44%). Which is the better fit depends on your goals.
| LTC | MRK | |
|---|---|---|
Market Cap | $2.15B | $307.25B |
Sector | Real Estate | Health |
52-Week High | $41.92 | $129.52 |
52-Week Low | $33.98 | $77.60 |
Enterprise Value | $2.99B | $350.66B |
Dividend Yield | 5.44% | 2.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LTC Properties trades at $41.92, up 0.41% with a bullish technical outlook. The REIT shows strong fundamentals with 2025 revenue of $263M and net income of $118M, supported by a 67.3% gross margin. Recent acquisitions expand its SHOP portfolio, targeting demographic trends in senior housing. Analyst sentiment is mixed with 27% buy ratings amid recent earnings misses.
Outlook: Growth driven by strategic acquisitions and aging demographics, but execution risks and debt levels warrant caution. Near-term focus on Q2 2026 earnings (expected EPS $0.48) as a key catalyst. Dividend yield of ~5.4% provides income appeal.
Merck (MRK) trades at $126.02, down 1.16% on the day, with a neutral technical signal and bullish moving averages. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of -$1.28 beating expectations. Revenue grew to $65.01B in 2025, and net income margin improved to 28.07%. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid competitive pressures.
The outlook for MRK is positive, supported by robust fundamentals and analyst consensus, but risks include patent expirations and regulatory challenges. With a consensus price target of $137.30 offering ~9% upside, the stock presents a compelling opportunity for growth investors, though volatility from macroeconomic factors warrants caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About LTC Properties Inc
LTC Properties Inc is a healthcare facility real estate investment trust. The company operates one segment that works to invest in healthcare facilities through mortgage loans, property lease transactions, and other investments. LTC generates all of its revenue in the United States. LTC is an active capital provider in the seniors housing and health care real estate industry. The company has been actively engaged with its operating partners to create a growing pipeline of projects. LTC considers merger and acquisition investment as a component of its operational growth strategy.
Read more on LTC →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
